BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-02-14 16:47 |
BerGenBio ASA: Exercise of share options and increase of capital
|
English | 1.9 KB | ||
| 2019-02-12 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
|
English | 1.3 MB | ||
| 2019-02-12 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
|
English | 5.7 MB | ||
| 2019-02-12 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
|
English | 55.7 KB | ||
| 2019-02-12 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
|
English | 7.2 KB | ||
| 2019-02-05 06:00 |
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presenta…
|
English | 1.9 KB | ||
| 2019-02-04 12:25 |
BerGenBio announces the allocation of R&D grant of up to NOK 12m awarded by Res…
|
English | 4.2 KB | ||
| 2019-01-21 06:00 |
BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AX…
|
English | 6.3 KB | ||
| 2019-01-09 11:18 |
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL A…
|
English | 5.3 KB | ||
| 2019-01-08 06:00 |
BerGenBio to present company overview at Biotech Showcase 2019 during annual J.…
|
English | 1.4 KB | ||
| 2019-01-04 06:00 |
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating S…
|
English | 7.0 KB | ||
| 2018-12-15 10:11 |
BerGenBio announces a change to its Board of Directors
|
English | 1.3 KB | ||
| 2018-12-12 06:00 |
BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor…
|
English | 4.8 KB | ||
| 2018-12-11 13:23 |
Financial calendar
|
English | 644 bytes | ||
| 2018-12-03 02:15 |
BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positiv…
|
English | 7.2 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
